The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to 59 years old who are at increased risk for severe illness from respiratory ...
CAMBRIDGE, MA / ACCESS Newswire / August 27, 2025 / Moderna, Inc. (MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Applications ...
WASHINGTON -- Moderna submitted its application to the U.S. Food and Drug Administration for emergency use authorization of its updated COVID-19 vaccine booster for use in people age 18 and older, the ...
Moderna CEO Stéphane Bancel positions 2026 as a catalyst-rich year driven by new vaccine launches, late-stage oncology data, ...
Americans could soon see a major increase in access to COVID-19 vaccine booster shots. On Friday, the U.S. Food and Drug Administration (FDA) announced its Vaccines and Related Biological Products ...
The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.
The Food and Drug Administration is delaying a decision on authorizing Moderna Inc.’s MRNA -1.69% COVID-19 vaccine for adolescents to assess whether the shot may lead to heightened risk of a rare ...
Moderna (MRNA) and other biopharma companies focused on developing vaccines are trading in the red on Monday following comments from FDA official Vinay Prasad, who oversees vaccinations, that future ...
13d
Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine
Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback